|Bid||2.7500 x 1800|
|Ask||3.0000 x 800|
|Day's Range||2.7700 - 2.9150|
|52 Week Range||1.7000 - 48.9000|
|Beta (3Y Monthly)||2.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
GAITHERSBURG, Md., March 21, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the.
Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.Source: Shutterstock Altimmune (NASDAQ:ALT) says that it saw strong results from an extension to the study that has it checking in on patients one year after its completion. This includes 100% of patients that returned for the study extension still being seroprotected.The Altimmune news about its intranasal influenza vaccine candidate NasoVAX notes that patients in the extension were also saw a seroconversion rate that was unchanged from last year. It is also worth noting that these patients were from the highest dosage level of the study.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market," Vipin Garg, Ph.D., President and CEO of Altimmune, said in a statement. "Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets." * Top 7 Service Sector Stocks That Will Pay You to Own Them The original study from Altimmune about using NasoVAX as an influenza vaccine had 13 people receiving the highest dosage of the vaccine. All 13 were invited to return for the extension, but only eight chose to do so.ALT stock was up 15% as of noon Tuesday and is up 11% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data appeared first on InvestorPlace.
Shares of Altimmune Inc. soared 36% in active premarket trade Tuesday, after the immunotherapeutics company reported "additional positive data" from its flu treatment and said it was seeking development and commercialization partnerships. Volume swelled to more than 1.5 million shares, compared with the full-day average of about 1.7 million shares. The company said a phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate showed that 100% of the evaluated subjects remained seroprotected, and the rate was unchanged more than a year after vaccination. "Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program," said Chief Executive Vipin Garg. "This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets. We are currently engaged in a rigorous acquisition review process focused on novel immunotherapeutic approaches for cancer, including immunostimulants and oncolytic viruses, and innovative product candidates for liver diseases." The stock has rallied 40.3% year to date through Monday, but has plunged 94% over the past 12 months, while the S&P 500 has climbed 13% the past three months and gained 4.4% the past year.
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated that 100% of the evaluated subjects remained seroprotected, and the seroconversion rate was unchanged more than one year after vaccination. Subjects from the highest dose group of the study were invited to return as part of a study extension to evaluate the duration of immunity 1-year post-vaccination.
GAITHERSBURG, Md., March 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg, Ph.D., President and Chief.
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-funded units receiving gross proceeds of $14 million. On March 8, 2019, the Company disclosed approximately $34.4 million in cash, cash equivalents and restricted cash as of December 31, 2018. Altimmune intends to use the cash on hand together with the net proceeds of approximately $12.7 million from this offering for the continued advancement and development activities for its product pipeline, strategic growth opportunities (including potential acquisitions and/or licensing transactions), and general working capital purposes.
Each common unit is being sold at a public offering price of $3.21 and consists of one share of common stock and 0.70 of a warrant to purchase one share of common stock at an exercise price of $3.21. Each pre-funded unit is being sold at a public offering price of $3.20 and consists of a pre-funded warrant to purchase one share of common stock at an exercise price of $0.01 per share and 0.70 of a warrant to purchase one share of common stock at an exercise price of $3.21.
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be presented on April 12, 2019 at The International Liver Congress sponsored by The European Association for the Study of the Liver (EASL) being held in Vienna, Austria April 10-14, 2019. As previously announced, this study met its primary endpoint of safety and showed that HepTcell treatment was associated with increased HBV-specific cellular immune responses.
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further expand its pipeline. As previously announced in September 2018, a monovalent version of NasoVAX, Altimmune's intranasally administered influenza vaccine candidate, elicited statistically significant mucosal antibody responses not seen with the commercially available injectable vaccine Fluzone®, and a nearly 6-fold higher median cellular immune response compared to Fluzone. In addition, the NasoVAX hemagglutination inhibition (HAI) antibody response was stable over the six-month follow-up period, while antibody titers elicited by Fluzone fell over 50% over the same period. The Company is now conducting an extension study for previous Phase 2a study participants to measure further durability of HAI responses one year after vaccination and will be evaluating other clinical measures of NasoVAX immunogenicity.
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as its President and Chief Executive Officer succeeding Bill Enright, current President and Chief Executive Officer, effective November 30. “Vipin was chosen in a very competitive selection process and we are very excited to have him join Altimmune as President and CEO,” said Mitch Sayare, Chairman of the Board of Altimmune. “His extensive experience and success in building, managing, and financing private and public biotech companies makes him an extraordinary fit for Altimmune.
NEW YORK, NY / ACCESSWIRE / November 23, 2018 / It was an eventful day of trading for Altimmune which saw gains of almost 10% despite any significant news. Shares of Johnson & Johnson were dragging lower after a U.S. appeals court refused to stop generic versions of its prostate-cancer drug Zytiga from entering the market. Altimmune, Inc. shares closed up nearly 10% on about 3.9 million shares traded on Wednesday.
GAITHERSBURG, Md., Nov. 13, 2018 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three and nine months.
The chief executive will stay in his role, and on the board, until his successor is appointed or early next year, whichever comes first.
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...
According to Altimmune (NASDAQ:ALT), the company has entered into a purchase agreement with a several institutional investors. The common units include one common share of Altimmune stock, as well as a warrant to purchase an additional share for the same price. It also includes a warrant to purchase an additional share of ALT stock for a price of $5.39.
NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Shares of Altimmune were collapsing in Friday’s session as the company announced the pricing of an underwritten public offering. Shares of Aytu Biosciences were seeing gains of over 13% despite any significant news. Aytu BioScience, Inc. shares were up 13.11% on Friday on nearly 2.8 million shares traded.
Shares of Molecular Templates were also exploding on the news that the company had entered into an agreement with Japan's Takeda Pharmaceutical Co Ltd for jointly developing CD38-targeted ETNs for treating patients with diseases such as multiple myeloma. Molecular Templates, Inc. shares closed up 52.44% on a little over 7 million shares traded yesterday. The clinical-stage oncology company was exploding on the news that it had announced an agreement with Japan's Takeda Pharmaceutical Co Ltd for jointly developing CD38-targeted ETNs for treating patients with diseases such as multiple myeloma.